CEPI: Broadly protective vaccine against SARS-CoV-2 variants (BPCoV2)

CEPI, the Coalition for Epidemic Preparedness Innovations launched a call for development of broadly protective vaccines against SARS-CoV-2 variants (BPCoV2).

Subsidy: not specified

Total Budget: $200M (for both BPCoV2 and BPBC)

Deadline: 31 May 2021 (Application will require one step, the submission of an Expression of Interest (EOI). An EOI may be submitted at any time and reviews will occur on a bi-monthly rolling basis.)

Project duration: 2 years

Consortium: Single applicant or a consortium are both eligible. This call is open, worldwide, to research and development organisations with expertise in vaccine development (at least one of the partners should have experience in human vaccine development and have a track record of bringing vaccine candidates through to human clinical trials in the past 5 years).

Scope: The main focus of this call is the research and development of novel immunogens for vaccine constructs able to elicit durable broadly protective responses.

Developed vaccine should be a broadly protective vaccine against new emerging variants and variants of concern of the SARS-CoV-2 virus (BPCoV2). Projects should aim to achieve clinical proof-of-concept.

The broadly protective vaccine against SARS-CoV-2 variants (BPCoV2) should have a minimal Target Product Profile (TPP) that aims to prevent disease caused by circulating SARS-CoV-2 variants of concern and emergent variants of interest. As these vaccines have the potential to help tackle the ongoing pandemic, as well as avoid costly and time-consuming strain adaptation, a more aggressive timeline for their development will be sought. Established and proven vaccine platforms are desired that facilitate rapid development and offer significant manufacturing scale up potential and access to vulnerable populations with potential Lower and Middle Income Country (LMIC) manufacturing.

Read more on the CEPI website

About CEPI

CEPI is an innovative global partnership between public, private, philanthropic, and civil society organisations launched in Davos in 2017 to develop vaccines to stop future epidemics. Their mission is to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks.

CEPI recently also launched a call for development of broadly protective vaccines against Betacoronavirus (BPBC). Read more about the CEPI BPBC grant.

To get free funding updates, including all new opportunities for research related to COVID-19, subscribe to Catalyze Alerts.